Providing New Cellular Medicine Solutions Through Research Advancements
Improving Life Through Bioscience
Providing New Cellular Medicine Solutions Through Research Advancements
Improving Life Through Bioscience
About Summa
Summa Bio-Solutions, Inc. is a commercially driven biotechnology company formed by its parent company Tithon Biotech, Inc. ("Tithon") to engage in the development of cellular medical solutions addressing various degenerative medical conditions affecting both humans and animals. Our technology results from years of both private and university research and development by pioneers in the fields of biotechnology and machine learning, in collaboration with medical practitioners within various fields of medicine throughout the world.
Our Vision
Our vision is to develop and to provide medical solutions, based upon our advanced new discoveries, to aid humans and animal around the world who are suffering from various types of degenerative medical conditions.
Our Mission
Through the efforts and dedication of our science team, and those collaborators within the medical community who share our vision and mission, we pursue our vision tirelessly, seeking new means to relieve suffering from degenerative medical conditions in humans and animals.
Our Core Technology
“nPSC" Technology
Naturally Occurring Pluripotent Stem Cells
A proprietary method, process and procedure to easily isolate and recover, from human and animal peripheral blood, abundant quantities of a naturally occurring pluripotent stem cell with demonstrated applications in human and animal therapeutics, diagnostics, tissue engineering and production of 3D organoids and ideal for cell banking.
"AD-MSC-CM" Technology
Adipose Derived Mesenchymal Stem Cell Conditioned Medium
A novel technology developed for the production of a Stem Cell Conditioned Medium containing the secretions of trophic and immuno-regulatory factors present in the culture medium of a proprietary line of immortalized Adipose Derived Mesenchymal Stem Cells that were carefully screened and selected due to their verified disease-free-state and high level of desired secretory factors demonstrated to inhibit inflammatory conditions.
Our Research & Development
nPSC Technology Advancements
3D ORGANOID Development Advancements
3D ORGANOID Development Advancements
Applications of Our nPSC Technology
3D ORGANOID Development Advancements
3D ORGANOID Development Advancements
3D ORGANOID Development Advancements
Commercial Development of Our Various
3D Organoid Tissues
AD-MSC-CM Technology Advancements
3D ORGANOID Development Advancements
AD-MSC-CM Technology Advancements
Successful demonstration of safety and efficacy of Our AD-MSC-CM Product candidate through Initial Laboratory Mouse Testing